Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1221

1.

Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.

Bangalore S, Breazna A, DeMicco DA, Wun CC, Messerli FH; TNT Steering Committee and Investigators.

J Am Coll Cardiol. 2015 Apr 21;65(15):1539-48. doi: 10.1016/j.jacc.2015.02.017.

PMID:
25881936
2.

Sex, Prescribing Practices and Guideline Recommended, Blood Pressure, and LDL Cholesterol Targets at Baseline in the BARI 2D Trial.

Magee MF, Tamis-Holland JE, Lu J, Bittner VA, Brooks MM, Lopes N, Jacobs AK, Study Group B2.

Int J Endocrinol. 2015;2015:610239. Epub 2015 Mar 19.

3.

Response: “Actually, it’s more of a guideline than a rule”.

Halperin JL.

J Am Coll Cardiol. 2015 Feb 3;65(4):400. No abstract available.

PMID:
25793247
4.
5.

Atheroma progression in hyporesponders to statin therapy.

Kataoka Y, St John J, Wolski K, Uno K, Puri R, Tuzcu EM, Nissen SE, Nicholls SJ.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):990-5. doi: 10.1161/ATVBAHA.114.304477. Epub 2015 Feb 26.

PMID:
25722430
6.

Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.

Hsue PY, Bittner VA, Betteridge J, Fayyad R, Laskey R, Wenger NK, Waters DD.

Am J Cardiol. 2015 Feb 15;115(4):447-53. doi: 10.1016/j.amjcard.2014.11.026. Epub 2014 Nov 29.

PMID:
25637322
7.

Navigating patient preference and guidelines as a fellow.

Gosain P.

J Am Coll Cardiol. 2015 Feb 3;65(4):398-9. doi: 10.1016/j.jacc.2014.12.006. No abstract available.

PMID:
25634841
8.

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.

Stoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen MJ, Pedersen TR, Hovingh GK; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.

Heart. 2015 Mar;101(5):356-62. doi: 10.1136/heartjnl-2014-306906. Epub 2015 Jan 16.

PMID:
25595417
9.
11.

Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.

Komukai K, Kubo T, Kitabata H, Matsuo Y, Ozaki Y, Takarada S, Okumoto Y, Shiono Y, Orii M, Shimamura K, Ueno S, Yamano T, Tanimoto T, Ino Y, Yamaguchi T, Kumiko H, Tanaka A, Imanishi T, Akagi H, Akasaka T.

J Am Coll Cardiol. 2014 Dec 2;64(21):2207-17. doi: 10.1016/j.jacc.2014.08.045. Epub 2014 Nov 24.

PMID:
25456755
12.

Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.

Maddox TM, Borden WB, Tang F, Virani SS, Oetgen WJ, Mullen JB, Chan PS, Casale PN, Douglas PS, Masoudi FA, Farmer SA, Rumsfeld JS.

J Am Coll Cardiol. 2014 Dec 2;64(21):2183-92. doi: 10.1016/j.jacc.2014.08.041. Epub 2014 Nov 19.

PMID:
25447259
13.

Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial.

McAlister FA, Majumdar SR, Lin M, Bakal J, Fradette M, Anderson T.

Can J Cardiol. 2014 Dec;30(12):1627-32. doi: 10.1016/j.cjca.2014.07.008. Epub 2014 Jul 16.

PMID:
25307535
14.

Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.

Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ.

JACC Cardiovasc Imaging. 2014 Oct;7(10):1013-22. doi: 10.1016/j.jcmg.2014.04.019. Epub 2014 Sep 17.

PMID:
25240453
15.

High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.

Stegman B, Puri R, Cho L, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nissen SE, Nicholls SJ.

Diabetes Care. 2014 Nov;37(11):3114-20. doi: 10.2337/dc14-1121. Epub 2014 Sep 4.

PMID:
25190674
16.

Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies.

Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, Dandona S, Roberts R, Quyyumi AA, Chen HH, Stewart AF.

PLoS One. 2014 Sep 2;9(9):e106294. doi: 10.1371/journal.pone.0106294. eCollection 2014.

17.
18.

Update on the NCEP ATP-III emerging cardiometabolic risk factors.

Eckel RH, Cornier MA.

BMC Med. 2014 Aug 26;12:115. doi: 10.1186/1741-7015-12-115. Review.

19.

Statins for children with familial hypercholesterolemia.

Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E.

Cochrane Database Syst Rev. 2014 Jul 23;7:CD006401. doi: 10.1002/14651858.CD006401.pub3. Review.

PMID:
25054950
20.

Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.

Page MM, Ekinci EI, Jones RM, Angus PW, Gow PJ, O'Brien RC.

Intern Med J. 2014 Jun;44(6):601-4. doi: 10.1111/imj.12444. Review. Erratum in: Intern Med J. 2014 Oct;44(10):1050.

PMID:
24946816
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk